Development ofMB-2003, a novel monoclonal antibody (mAB) based countermeasure with antiviral activity against Ebola virus

Project: Other project

StatusFinished
Effective start/end date4/19/165/31/17

Funding

  • Mapp Biopharmaceutical Inc: $360,181.00